Gastrointestinal disorder
With DD patients for gastrointestinal disorder (20 trials), the pooled
results showed a statistical increase in Roxadustat (RR: 1.30, 95% CI:
1.03-1.63, p=0.03, I2=77.3%) and Enarodustat (RR:
6.92, 95% CI: 1.51-31.69, p=0.01, I2=77.3%), but no
significant differences in Daprodustat, Desidustat, Vadadustat, and
Molidustat (Figure 4).